Sona Nanotech Inc. Stock

Equities

SONA

CA83541C1059

Medical Equipment, Supplies & Distribution

Delayed Canadian Securities Exchange 11:23:29 2024-04-30 EDT 5-day change 1st Jan Change
0.35 CAD 0.00% Intraday chart for Sona Nanotech Inc. -16.67% +45.83%
Sales 2022 - Sales 2023 - Capitalization 16.64M 22.89M
Net income 2022 -2M -2.75M Net income 2023 -2M -2.75M EV / Sales 2022 -
Net Debt 2022 444K 611K Net Debt 2023 412K 567K EV / Sales 2023 -
P/E ratio 2022
-4.2 x
P/E ratio 2023
-6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 84.54%
More Fundamentals * Assessed data
Dynamic Chart
1 week-16.67%
Current month-22.22%
1 month-22.22%
3 months+25.00%
6 months+94.44%
Current year+45.83%
More quotes
1 week
0.35
Extreme 0.345
0.42
1 month
0.33
Extreme 0.33
0.56
Current year
0.24
Extreme 0.24
0.56
1 year
0.14
Extreme 0.135
0.56
3 years
0.02
Extreme 0.02
1.82
5 years
0.01
Extreme 0.01
16.05
10 years
0.00
Extreme 0
16.05
More quotes
Managers TitleAgeSince
Founder - 04-11-16
Founder - 04-11-16
Chief Executive Officer 55 20-07-06
Members of the board TitleAgeSince
Chairman - 20-11-02
Director/Board Member - 22-01-03
Director/Board Member 59 19-12-18
More insiders
Date Price Change Volume
24-04-30 0.35 0.00% 5 256
24-04-29 0.35 -14.63% 120,130
24-04-26 0.41 -2.38% 2,214
24-04-25 0.42 +5.00% 22,525
24-04-24 0.4 -4.76% 28,225

Delayed Quote Canadian Securities Exchange, April 30, 2024 at 11:23 am

More quotes
Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.
More about the company